PLoS Pathogens (May 2023)

Distinct immune responses associated with vaccination status and protection outcomes after malaria challenge.

  • Damian A Oyong,
  • Fergal J Duffy,
  • Maxwell L Neal,
  • Ying Du,
  • Jason Carnes,
  • Katharine V Schwedhelm,
  • Nina Hertoghs,
  • Seong-Hwan Jun,
  • Helen Miller,
  • John D Aitchison,
  • Stephen C De Rosa,
  • Evan W Newell,
  • M Juliana McElrath,
  • Suzanne M McDermott,
  • Kenneth D Stuart

DOI
https://doi.org/10.1371/journal.ppat.1011051
Journal volume & issue
Vol. 19, no. 5
p. e1011051

Abstract

Read online

Understanding immune mechanisms that mediate malaria protection is critical for improving vaccine development. Vaccination with radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) induces high level of sterilizing immunity against malaria and serves as a valuable tool for the study of protective mechanisms. To identify vaccine-induced and protection-associated responses during malarial infection, we performed transcriptome profiling of whole blood and in-depth cellular profiling of PBMCs from volunteers who received either PfRAS or noninfectious mosquito bites, followed by controlled human malaria infection (CHMI) challenge. In-depth single-cell profiling of cell subsets that respond to CHMI in mock-vaccinated individuals showed a predominantly inflammatory transcriptome response. Whole blood transcriptome analysis revealed that gene sets associated with type I and II interferon and NK cell responses were increased in prior to CHMI while T and B cell signatures were decreased as early as one day following CHMI in protected vaccinees. In contrast, non-protected vaccinees and mock-vaccinated individuals exhibited shared transcriptome changes after CHMI characterized by decreased innate cell signatures and inflammatory responses. Additionally, immunophenotyping data showed different induction profiles of vδ2+ γδ T cells, CD56+ CD8+ T effector memory (Tem) cells, and non-classical monocytes between protected vaccinees and individuals developing blood-stage parasitemia, following treatment and resolution of infection. Our data provide key insights in understanding immune mechanistic pathways of PfRAS-induced protection and infective CHMI. We demonstrate that vaccine-induced immune response is heterogenous between protected and non-protected vaccinees and that inducted-malaria protection by PfRAS is associated with early and rapid changes in interferon, NK cell and adaptive immune responses. Trial Registration: ClinicalTrials.gov NCT01994525.